Apellis Pharmaceuticals Inc Q4 2020 Earnings Call Transcript - Thomson StreetEvents

Apellis Pharmaceuticals Inc Q4 2020 Earnings Call Transcript

Apellis Pharmaceuticals Inc Q4 2020 Earnings Call Transcript - Thomson StreetEvents
Apellis Pharmaceuticals Inc Q4 2020 Earnings Call Transcript
Published Feb 25, 2021
14 pages (8944 words) — Published Feb 25, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of APLS.OQ earnings conference call or presentation 25-Feb-21 9:30pm GMT

  
Brief Excerpt:

...Operator Good afternoon. My name is Valerie, and I will be your conference operator today. At this time, I would like to welcome everyone to Apellis Pharmaceuticals Fourth Quarter and Full Year 2020 Fiscal Results Conference Call. Today's call is being recorded and a replay will available at apellis.com. I would now like to turn the call over to Tracy Vineis, Vice President of Communications at Apellis. Tracy Vineis ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Apellis Pharmaceuticals Inc
Ticker
APLS.OQ
Time
9:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Matthew W. Luchini - BMO Capital Markets Equity Research - Analyst : So first, on PNH, commercially, I guess I'd love to get a little sense as to what your internal market research is telling you about the initial launch. And what I'm really looking for is a little bit more of the color around things like are patients -- are your doctors telling you that the patients are asking for the drug? Are they planning to call patients in versus waiting for the next visit? Any kind of color there that could help sort of set our expectations around what the initial launch is going to look like? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 25, 2021 / 9:30PM, APLS.OQ - Q4 2020 Apellis Pharmaceuticals Inc Earnings Call And then secondly, just kind of a housekeeping question. It looks like R&D saw a pretty decent sequential step down in 4Q. And I'm just wondering if that's something that we should think about as sort of the new baseline going forward? Or how we should think about that as we think forward into this year and beyond?

Table Of Contents

Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually Transcript – 2021-06-30 – US$ 54.00 – Edited Transcript of APLS.OQ corporate analyst meeting</ 30-Jun-21 4:30pm GMT

Apellis Pharmaceuticals Inc at Bank of America NAPA Healthcare Conference Transcript – 2021-06-16 – US$ 54.00 – Edited Transcript of APLS.OQ presentation 16-Jun-21 8:30pm GMT

Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript – 2021-06-10 – US$ 54.00 – Edited Transcript of APLS.OQ presentation 10-Jun-21 12:00pm GMT

Apellis Pharmaceuticals Inc EMPAVELI FDA Approval Call Transcript – 2021-05-17 – US$ 54.00 – Edited Transcript of APLS.OQ conference call or presentation 17-May-21 12:00pm GMT

Apellis Pharmaceuticals Inc Q1 2021 Earnings Call Transcript – 2021-04-28 – US$ 54.00 – Edited Transcript of APLS.OQ earnings conference call or presentation 28-Apr-21 8:30pm GMT

Apellis Pharmaceuticals Inc Virtual Investorm Meeting - Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) Transcript – 2021-01-28 – US$ 54.00 – Edited Transcript of APLS.OQ corporate analyst meeting</ 28-Jan-21 3:00pm GMT

Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-12 – US$ 54.00 – Edited Transcript of APLS.OQ presentation 12-Jan-21 3:50pm GMT

Apellis Pharmaceuticals Inc Sobi Strategic Collaboration Conference Call Transcript – 2020-10-27 – US$ 54.00 – Edited Transcript of APLS.OQ conference call or presentation 27-Oct-20 12:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Apellis Pharmaceuticals Inc Q4 2020 Earnings Call Transcript" Feb 25, 2021. Alacra Store. May 04, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2020-Apellis-Pharmaceuticals-Inc-Earnings-Call-T13646507>
  
APA:
Thomson StreetEvents. (2021). Apellis Pharmaceuticals Inc Q4 2020 Earnings Call Transcript Feb 25, 2021. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2020-Apellis-Pharmaceuticals-Inc-Earnings-Call-T13646507>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.